RARE vs STOK
RARE: Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases. STOK: Stoke Therapeutics uses its proprietary TANGO protein upregulation platform to develop treatments for severe genetic diseases, with lead candidate zorevunersen in clinical trials for Dravet syndrome.
Side-by-side fundamentals
| Metric | RARE | STOK | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $26.89 | $29.31 | |
| Market cap as of 2026-07-30 | $2.6B | $1.8B | |
| PEG as of 2026-07-30 | -1.11 | n/a | |
| Net margin as of 2026-07-30 | -91.0% | -529.2% | RARE higher |
| Gross margin as of 2026-07-30 | +83.6% | n/a | |
| Operating margin as of 2026-07-30 | -83.8% | -577.5% | RARE higher |
| ROE as of 2026-07-30 | -414.2% | -48.8% | STOK higher |
| ROA as of 2026-07-30 | -45.7% | -42.3% | STOK higher |
| Debt / equity as of 2026-07-30 | 90.54 | 0.00 | STOK lower |
| Revenue growth (YoY) as of 2026-07-30 | +13.3% | -83.2% | RARE higher |
| Revenue CAGR (3y) SEC XBRL | +22.8% | +145.9% | STOK higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-30 | 0.30 | 1.22 | |
| 1-year return as of 2026-07-27 close | -1.6% | +123.7% | STOK higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.